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The aim of our study was an evaluation of the expression of cell proliferation
markers (PCNA and Ki-67) in conjunctival and eyelid papillomas and squamous
and basal cell cancers. A series of 9 cases of squamous cell cancer (SCC), 15
cases of basal cell cancer (BCC) and 43 cases of squamous cell papilloma (SCP)
were assessed using the immunohistochemical method with monoclonal anti-
bodies. PCNA overexpression was observed in 100% of SCP, in 88.8% of SCC
and in 100% of BCC cases. Ki-67 overexpression was seen in 32.5% of cases of
SCP, in 22.2% of SCC and in 66.6% of BCC. The results showed that an evalua-
tion of Ki-67 expression is the most valuable cell proliferation marker.
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INTRODUCTION
Conjunctival and eyelid papilloma, as well as
squamous and basal cell cancers, are common tu-
mours of the epithelium and are known to occur
in both children and adults. PCNA (proliferating
cell nuclear antigen) is a co-factor for DNA poly-
merase delta in S phase and also during DNA syn-
thesis associated with DNA damage repair mech-
anism. PCNA expression is a useful marker of cell
proliferation in both normal and neoplastic tis-
sues [4]. Ki-67 expression occurs during the phase
of the cell cycle designated as late G1, S, M, and
G2, while during the G0 phase, the antigen can-
not be detected [1]. The aim of our study was to
evaluate Ki-67 and PCNA expression in squamous
cell papilloma as well as in squamous and basal
cell cancers. There are no data related to Ki-67
and PCNA expression in conjunctival and eyelid
papilloma.
MATERIAL AND METHODS
A series of 67 benign and malignant conjunctival
and eyelid lesions were examined, comprising 9 cas-
es of squamous cell cancer (SCC), 15 cases of basal
cell cancer (BCC) and 43 cases of squamous cell pap-
illoma (SCP). Material for histopathological examina-
tion was fixed in formalin, routinely processed and
paraffin embedded. Immunohistochemical analyses
were carried out using monoclonal antibodies DAKO/
/PCNA, M0879; DAKO/Ki-67, M7240. The reaction
performed in LSAB was followed by the use of chro-
mogen AEC to visualise the antigen/antibody com-
plex. Scores in SCC and BCC groups were based on
the following scale: (–) below 10% of the cells show-
ing positive reaction for PCNA and Ki-67 protein, and
(+) above 10% of the cells with positive immunostain-
ing. In the papilloma group we defined as (–) nega-
tive immunostaining for the proteins examined or
when Ki-67 and PCNA expression was restricted only
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to the basal layer. PCNA and Ki-67 protein expression
was defined as (+) in both the basal and parabasal
layers and in the whole thickness of the epithelium.
The values obtained were subjected to statistical anal-
ysis with the use of the Fisher or chi-square test. Val-
ues at p < 0.05 were considered significant.
RESULTS AND DISCUSSION
Both PCNA and Ki-67 protein expression was re-
stricted to the nucleus. In the papilloma group (SCP),
with ages ranging from 18 to 94 years (mean age
55.8), most cases were localised on the eyelid. Cel-
lular dysplasia was observed in 7 cases of SCP. PCNA
protein expression was observed in 43 cases (100%).
In the whole thickness of the epithelium PCNA ex-
pression was noticed in 11 out of 43 cases of SCP
(25.5%) (Fig. 1, 2). In papilloma with dysplasia PCNA
expression was restricted to the basal and parabasal
layer in 6 out of 7 cases and only in 1 case was pos-
itive immunostaining for PCNA seen in the whole
thickness of the epithelium. Ki-67 protein expression
was assessed as positive in 14 out of 43 cases (32.5%)
(Fig. 3). Only in 2 out of 7 cases of papilloma with
cellular dysplasia was Ki-67 expression seen and only
in the basal and parabasal layers. In the SCC group
ages ranged from 42 to 82 years and in the BCC
group from 44 to 87 years (the mean age for both
groups was 64.9 years). SCCs were evaluated using
histological tumour grading (G stage) as G1, G2 and
G3, with 3 cases at each stage. In G2 and G3 tu-
mours mainly tricholemmal differentiation was ob-
served and pT ranged from pT2 to pT3. In the SCC
group a PCNA positive reaction was observed in 8 out
of 9 cases (88.8%), in 2 out of 3 cases at the G1
stage and in 3 out of 3 cases at the G2 stage and G3
stage. Ki-67 protein positive immunostaining was
seen only in 22.2% (2 out of 3 cases at the G3 stage)
(Fig. 4). The BCC group was divided into 3 subgroups:
nodular (4 cases), infiltrative (1 case) and mixed
(10 cases). In the BCC group PCNA expression was
noticed in 100% of cases: 4 cases of the nodular
type, 1 case of infiltrative and 10 cases of the mixed
type of basal cell carcinoma (Fig. 5). Ki-67 protein
positive reaction was shown in 66.6%: 4 cases of
the nodular type of BCC, 1 case of infiltrative and 5
cases of the mixed type of basal cell cancer (Fig. 6).
There is no data connected with Ki-67 and PCNA
expression in conjunctival and eyelid papilloma. How-
ever Lu et al. [4] showed PCNA overexpression in the
basal layer in 20 cases of skin warts, in 32 cases in the
basal and parabasal layers and in 36 out of 90 cases
of skin warts in the whole thickness of epithelium.
In our prior study strong PCNA positive immunostain-
ing was noticed mainly in the basal and parabasal
layers of papilloma, as well as in cells of superficial
layers in the papilloma with dysplasia [6]. Kręcicki et
al. [3] observed PCNA overexpression in 69.9% of
dysplastic lesions of the larynx. Rabah et al. [5] ob-
served in laryngeal papillomatosis Ki-67 indices rang-
ing from 9% to 40%. Most of the stained cells were
in the basal layer. Koide et al. [2] observed locally
PCNA-positive cells in well differentiated and mod-
erately differentiated SCCs of the oesophagus. The
PCNA labelling index was significantly higher in the
basal cell cancer than in SCC. Stainbeck et al. [7]
observed increased PCNA immunoreactivity in highly
differentiated squamous cell cancer while, in con-
trast, more poorly differentiated carcinomas
showed strongly elevated proliferative activity
throughout the entire tumour mass. Barret et al. [1]
showed PCNA expression in more cases than Ki-67
in all types of BCC (nodular, infiltrative, sclerosing
and metatypical). A comparison of the immunore-
activity of PCNA and Ki-67 protein in conjunctival
and eyelid squamous cell papillomas and squamous
and basal cell cancers might suggest that the eval-
uation of Ki-67 expression is a more particular mark-
er of cell proliferation than PCNA expression. It
would seem expedient, therefore, to adapt differ-
entiated standards of proliferate activity and also
the markers examined by us in the evaluation of
cell proliferation in conjunctival and eyelid carcino-
genesis.
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Figure 5. PCNA positive immunostaining observed in basal cell
cancer. Magn. 200 ×.
Figure 1. PCNA overexpression observed in the basal and parabasal
layers of epithelium in eyelid squamous cell papilloma. Magn. 100 ×.
Figure 2. Ki-67 nuclear positive immunostaining seen in squamous cell
cancer with tricholemmal differentiation of the eyelid. Magn. 100 ×.
Figure 3. Ki-67 nuclear overexpression in squamous cell papilloma
of the eyelid seen in the basal and parabasal layers. Magn. 100 ×.
Figure 4. Ki-67 nuclear immunostaining seen in squamous cell
cancer. Magn 200 ×.
Figure 6. Ki-67 nuclear immunostaining observed in basal cell
cancer. Magn. 100 ×.
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